Shoot­ing for PhI­II, Spero tees up a new lead an­tibi­ot­ic in-li­censed cheap as it lines up $86M IPO

Late last week Spero Ther­a­peu­tics threw its S-1 in­to the IPO ring as the biotech queue for jump­ing in­to the pub­lic are­na was grow­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.